Plasma total phenytoin: A possibly misleading test in developing countries

Therapeutic Drug Monitoring

Volumn 21, Issue 2, 1999, Pages 155-160

  Fedler, Carolyn ^a   Stewart, Michael J ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

Albumin; Correction; Monitoring; Phenytoin

Indexed keywords

ALBUMIN; PHENYTOIN;

ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG PROTEIN BINDING; HUMAN; HYPOALBUMINEMIA; IMMUNOASSAY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH AFRICA;

ANTICONVULSANTS; DEVELOPING COUNTRIES; DRUG MONITORING; HUMANS; NUTRITION DISORDERS; PHENYTOIN; PROTEIN BINDING; SERUM ALBUMIN; SOUTH AFRICA;

EID: 0032897916     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199904000-00003     Document Type: Article

References (47)

1. Lund L, Lunde PK, Rane A, et al. F Plasma protein binding, plasma concentrations, and effects of diphenylhydantoin in man. Ann N Y Acad Sci 1971;179:723-8.
2. Boucher BA, Rodman JH, Jaresko GS, et al. Phenytoin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther 1988;44:675-83.
3. Peterson GM, Khoo BH, von Witt RJ. Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit 1991;13:415-9.
4. Lindow J, Wijdicks EF. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994;105:602-4.
5. Hvidberg EF, Dam M. Clinical Pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976;1:161-88.
6. Lund L, Berlin A, Lunde KM. Plasma protein binding of of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction and the plasma concentration in the cerebrospinal fluid. Clin Pharmacol Ther 1970 13:196-200.
7. Morselli PL Clinical pharmacokinetics in neonates. Clin Pharmacokinet 1976;1:81-98.
8. Perucca E. Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies. Clin Pharmacokinet 1984;91:71-8.
9. Koch-Weser J, Sellers EM. Binding of drugs to serum albumin. N Engl J Med 1976:294:311.
10. Beringer PM, Rho JP. Is routine measurement of free phenytoin concentrations rational? Ther Drug Monit 1995;17:381-2.
11. Whitlam JB, Brown KF. Ultrafiltration in serum protein binding determination. J Pharm Sci 1981;70:146-50.
12. Kurtz H Trunk H Weitz B Evaluation of methods to determine protein binding of drugs: Equilibrium dialysis, ultrafiltration, ultracentrifugation and gel filtration. Arzneimittel-Forschung 1977; 27:1373-80.
13. Jack L, Cunningham C, Watson ID, et al. Microscale ultracentrifugation as an alternative to ultrafiltration for the determination of the unbound fraction of phenytoin in human serum. Ann Clin Biochem 1986;23:603-7.
14. Oellerich M, Muller-Vahl H. The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin. Clin Pharmacokinet 1984;9:61-70.
15. Dasgupta A, Dean R, Saldana S, et al. Absorption of therapeutic drugs by barrier gels in serum separator blood collection tubes. Volume- and time-dependent reduction in total and free drug concentrations. Am J Clin Pathol 1994;101:456-61.
16. Cai WM, Leader WG, Porter WH, et al. Influence of serum separator tubes on total and free phenytoin concentrations and dosages. Ther Drug Monit 1993;15:427-30.
17. Ratnaraj N, Goldberg VD, Hjelm M. Temperature effects on the estimation of free levels of phenytoin carbamazepine and phenobarbitone. Ther Drug Monit 1990;12:465-72.
18. Allison TB, Comstock TJ. Temperature dependence of phenytoin-protein binding in serum: Effects of uremia and hypoalbuminemia. Ther Drug Monit 1988;10:376-81.
19. Dasgupta A, Dennen DA, Dean R, et al. Prediction of free phenytoin levels based on [total phenytoin]/[albumin] ratios. Potential errors with hypoalbuminemia. Am J Clin Pathol 1991;95:253-6.
20. Mauro LS, Mauro VF, Bachmann KA, et al. Accuracy of two equations in determining normalized phenytoin concentrations. Drug Intell Clin Pharm 1989;23:64-8.
21. Dager WE, Inciardi JF, Howe TL. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother 1995;29:667-70.
22. Winter E. Basic clinical pharmacokinetics. Spokane, WA: Applied Therapeutics, 1984.
23. Pospisil J, Pelclova DA. graphical nomogram method for predicting toxic concentrations of unbound phenytoin. Int J Clin Pharmacol Ther 1994;32:122-5.
24. Rimmer EM, Buss DC, Routledge PA, et al. Should we routinely measure free plasma phenytoin concentration? Br J Clin Pharmacol 1984;17:99-102.
25. Kilpatrick CJ, Wanwimolruk S, Wing LM. Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmacol 1984;17:539-46.
26. Liponi DF, Winter ME, Tozer TN. Renal function and therapeutic concentrations of phenytoin. Neurology 1984;34:395-7.
27. Baird-Lambert J, Manglick MP, Wall M, et al. Identifying patients who might benefit from free phenytoin monitoring. Ther Drug Monit 1987;9:134-8.
28. Levy RH, Schmidt D. Utility of free level monitoring of antiepileptic drugs. Epilepsia 1985;26:199-205.
29. Ohshima T, Hasegawa T, Johno I, et al. Variations in protein binding of drugs in plasma and serum. Clin Chem 1989;35:1722-5.
30. Zielmann S, Mielck F, Kahl R, et al. A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther Drug Monit 1994;16:139-44.
31. Dutkiewicz G, Wojcicki J, Gawronska-Szklarz B. The influence of hyperlipidemia on pharmacokinetics of free phenytoin. Neurol Neurochir Pol 1995;29:203-11.
32. Dasgupta A, Crossey MJ. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. Am J Med Sci 1997;313:75-9.
33. Doucet J, Fresel J, Hue G, et al. Protein binding of digitoxin, valproate and phenytoin in sera from diabetics. Eur J Clin Pharmacol 1993;45:577-9.
34. Reidenberg MM, Odar-Cederlof I, Bahr C, et al. Protein binding of diphenylhydantoin and desmethyimipramine in plasma from patients with poor renal function New Engl J Med 1971;285:264-7.
35. Odar-Cedarlof I, Borga O, et al. Kinetics of diphenylhydantoin in uremic patients: Consequences of reduced protein binding. Euro J Clin Pharmacol 1974:7:31.
36. Hooper WD, Bochner F, Eadie MJ, et al. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 1974;15:276-82.
37. Mabuchi H, Nakahashi HA major inhibitor of phenytoin binding to serum protein in uremia. Nephron 1988;48:310-4.
38. Dasgupta A, Abu-Alfa A. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds. Am J Clin Pathol 1992;98:19-25.
39. Tiula E, Neuvonen PJ. Effect of total drug concentration on the free fraction in uremic sera. Ther Drug Monit 1986;8:27-31.
40. Naidu S, Moodley J, Botha J, et al. The efficacy of phenytoin in relation to serum levels in severe pre-eclampsia and eclampsia. Br J Obstet Gynaecol 1992;99:881-6.
41. Painter MJ, Minnigh MB, Gaus L, et al. Neonatal phenobarbital and phenytoin binding profiles. J Clin Pharmacol 1994;34:312-7.
42. Markowsky SJ, Skaar DJ, Christie JM, et al. Phenytoin protein binding and dosage requirements during acute and convalescent phases following brain injury. Ann Pharmacother 1996;30:443-8.
43. Rane A, Lunde PK, Jailing B, et al. Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinaemic infants. J Paediatr 1971;78:877-82.
44. Reidenberg MM, Affrime M. Influence of disease on the binding of drugs to plasma proteins Ann N Y Acad Sci 1973;226:115-26.
45. Dasgupta A, Timmerman TG. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera. Ther Drug Monit 1996;18:97-9.
46. Blum RA, Schentag JJ, Gardner MJ, et al.The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers. Br J Clin Pharmacol 1995;39:35-85.
47. Toler SM, Wilkerson MA, Porter WH, et al. Severe phenytoin intoxication as a result of altered protein binding in AIDS. Drug Intell Clin Pharm 1990;24:698-700.